<DOC>
	<DOCNO>NCT00956280</DOCNO>
	<brief_summary>The purpose study characterize demographic clinical aspect , describe frequency type KRAS mutation Brazilian population sample advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Epidemiologic Study KRAS Mutation Brazilian Patients With Advanced Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological confirmation locally advance metastatic Non Small Cell Lung Cancer ( IIIBIV ) Tumour sample ( block slide ) available KRAS analysis Confirmation locally advance metastatic NSCLC ( IIIBIV ) exclusively cytology , tumour sample access . Previous treatment use MEK inhibitor regimen contain docetaxel ( previous treatment paclitaxel accept )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>The frequency type KRAS mutation sample Brazilian population advance NSCLC</keyword>
	<keyword>KRAS mutation population advance NSCLC</keyword>
</DOC>